Ocrevus Alternatives Compared
| Ocrevus (ocrelizumab) | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
|---|
| Ocrevus (ocrelizumab) | Kesimpta (ofatumumab) | Copaxone (glatiramer) |
|
|||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
Prescription only
Ocrevus is a CD20 monoclonal antibody that causes B-cells to self-destruct or disintegrate, reducing inflammation in people with MS. After an initial loading dose, it is given by IV infusion every... View more |
Prescription only
Prescribed for Multiple Sclerosis. Kesimpta may also be used for purposes not listed in this medication guide. |
Prescription only
Copaxone is a combination of four amino acids that may be given to treat relapsing forms of multiple sclerosis in adults. It has been shown to significantly reduce the number of relapses but may be... View more |
Related suggestions |
|||||||||||||||||||||||
| More about Ocrevus (ocrelizumab) | More about Kesimpta (ofatumumab) | More about Copaxone (glatiramer) | ||||||||||||||||||||||||
| Ratings & Reviews | ||||||||||||||||||||||||||
|
Ocrevus has an average rating of 5.3 out of 10 from a total of 176 ratings on Drugs.com. 41% of reviewers reported a positive effect, while 42% reported a negative effect. |
Kesimpta has an average rating of 6.8 out of 10 from a total of 74 ratings on Drugs.com. 51% of reviewers reported a positive effect, while 19% reported a negative effect. |
Copaxone has an average rating of 7.5 out of 10 from a total of 133 ratings on Drugs.com. 65% of reviewers reported a positive effect, while 17% reported a negative effect. |
||||||||||||||||||||||||
| Side Effects Experienced by Users Side effects are reported in Drugs.com user reviews and not clinically verified. | ||||||||||||||||||||||||||
View all Ocrevus side effects |
View all Kesimpta side effects |
View all Copaxone side effects |
||||||||||||||||||||||||
| Drug Class | ||||||||||||||||||||||||||
| Generic Availability | ||||||||||||||||||||||||||
|
N/A |
N/A |
|||||||||||||||||||||||||
| Pricing and Coupons * Prices are without insurance | ||||||||||||||||||||||||||
View all Ocrevus prices |
View all Kesimpta prices |
View all Copaxone prices |
||||||||||||||||||||||||
| Dosage Forms | ||||||||||||||||||||||||||
|
|
|
||||||||||||||||||||||||
| Brand Names | ||||||||||||||||||||||||||
|
N/A |
Other ofatumumab brands include: Arzerra | Other glatiramer brands include: Glatopa | ||||||||||||||||||||||||
| Half Life Drug half-life is the time required for plasma concentration to reduce to half its original value. | ||||||||||||||||||||||||||
|
624 hours |
1476 hours |
1 hour |
||||||||||||||||||||||||
| CSA Schedule 1 View glossary of CSA terms | ||||||||||||||||||||||||||
|
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
Not a controlled drug
Is not subject to the Controlled Substances Act. |
||||||||||||||||||||||||
| Pregnancy Category | ||||||||||||||||||||||||||
|
Summary unavailable. See the full pregnancy warnings document. |
Category C
Risk cannot be ruled out
See the full pregnancy warnings document. |
Category B
No proven risk in humans
See the full pregnancy warnings document. |
||||||||||||||||||||||||
| Drug Interactions | ||||||||||||||||||||||||||
|
A total of 434 drugs are known to interact with Ocrevus:
|
A total of 177 drugs are known to interact with Kesimpta:
|
A total of 1 drugs are known to interact with Copaxone:
|
||||||||||||||||||||||||
| Alcohol/Food/Lifestyle Interactions | ||||||||||||||||||||||||||
|
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
No known alcohol/food interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||
| Disease Interactions | ||||||||||||||||||||||||||
|
No known disease interactions. This does not necessarily mean no interactions exist. Always consult your healthcare provider. |
||||||||||||||||||||||||||
| First Approval Date | ||||||||||||||||||||||||||
|
March 28, 2017 |
N/A |
December 20, 1996 |
||||||||||||||||||||||||
| WADA Class View classifications | ||||||||||||||||||||||||||
|
N/A |
N/A |
N/A |
||||||||||||||||||||||||
| More Information | ||||||||||||||||||||||||||
| Patient Resources | ||||||||||||||||||||||||||
| Professional Resources | ||||||||||||||||||||||||||
| Related Treatment Guide | ||||||||||||||||||||||||||
1 The Controlled Substances Act (CSA) schedule information displayed applies to substances regulated under federal law. There may be variations in CSA schedules between individual states.
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.